Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297996 | 0.81 | RIPK1 (0.46) | CNR1RIPK1 | |
| SCHEMBL19177061 | 0.80 | CNR1 (0.48) | CNR1RIPK1 | |
| SCHEMBL24064221 | 0.79 | — | — | |
| SCHEMBL24002319 | 0.79 | RIPK1 (0.34) | CNR1RIPK1 | |
| SCHEMBL21415415 | 0.77 | RIPK1 (0.38) | CNR1RIPK1 | |
| SCHEMBL20144634 | 0.77 | GGT1 (0.33) | RIPK1 | |
| SCHEMBL14684132 | 0.75 | ALDH1A1 (0.34) | CNR1RIPK1 | |
| SCHEMBL20813616 | 0.74 | DGAT1 (0.31) | — | |
| SCHEMBL9499386 | 0.74 | CNR1 (0.34) | CNR1RIPK1 | |
| SCHEMBL22061841 | 0.73 | DNM1 (0.44) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346965-A1 | ENEDIYNE CONJUGATES | SYNAFFIX B.V. (NL) | 2023-11-02 | — | — | US | disclosed |
| US-11547763-B2 | Enediyne conjugates | SYNAHIX B.V. (NL) | 2023-01-10 | — | — | US | disclosed |
| US-20200297861-A1 | ENEDIYNE CONJUGATES | SYNAFFIX B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297861-A1 | ENEDIYNE CONJUGATES | ENY2, ZYX, TPD52L2 | CNR1 3575/4885RIPK1 977/4885 |
| US-20230346965-A1 | ENEDIYNE CONJUGATES | ENY2, ZYX, TPD52L2 | CNR1 3575/4885RIPK1 977/4885 |
| US-11547763-B2 | Enediyne conjugates | ENY2, ZYX, TPD52L2 | CNR1 3575/4885RIPK1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.